The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment

British Journal of Pharmacology

Volumn 125, Issue 4, 1998, Pages 767-770

  Pickavance, L ^a,c   Widdowson, P S ^a   King, P ^a   Ishii, S ^b   Tanaka, H ^b   Williams, G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

^c Diabet and Endocrinol Res Unit   (United Kingdom)

Author keywords

Diabetes; Impaired glucose tolerance; Insulin; MCC 555; Thiazolidinediones; ZDF rats

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; NETOGLITAZONE; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LONG TERM CARE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

AGE FACTORS; ANIMALS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRINKING; GLUCOSE; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, ZUCKER; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 0031728308     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702158     Document Type: Article

References (18)

1. CLARK, J.B. & PALMER, C.J. (1982). The diabetic Zucker rat - a new model for non-insulin dependent diabetes. Diabetes. 30, 126A.
2. DEFRONZO, R. (1988). The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37, 667-685.
3. FORMAN, B.M., TONTONOZ, P., CHEN, J., BRUN, R.P., SPIEGELMAN, B.M. & EVANS, R.M. (1995). 15-Deoxy-A12, 14 prostoglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell, 83, 803-812.
4. HARRIS, M.L. (1996). Impaired glucose tolerance - prevalence and conversion to NIDDM. Diabetes Med., 13 (3 suppl 2), S9-S11.
5. HARRIS, P.K. & KLETZIEN, R.F. (1994). Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene. Mol. Pharmacol., 45, 439-445.
6. ISHII, S., WASAKI, M., OHNE, T., UENO, H. & TANAKA, H. (1996). MCC-555: A highly potent thiazolidinedione lacking hematological and cardiac side-effects. Diabetes, 45 (suppl 2), P141A.
7. LEHMANN, J.M., MOORE, L.B., SMITH-OLIVER, T.A., WILKISON, W.O., WILLSON, T.M. & KLIEWER, S.A. (1995). An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome proliferator-activated receptorγ (PPARγ). J. Biol. Chem., 270, 12953-12956.
8. NOLAN, J.J., LUDVIK, B., BEERDSEN, P., JOYCE, M. & OLEFSKY, J. (1994). Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med., 331, 1188-1193.
9. PETERSON, R.G. (1994). The Zucker diabetic fatty (ZDF) rat. In Lessons from animal diabetes. ed. E. Shafrir. pp. 225-230. London: Smith-Gordon.
10. POLONSKY, K.S., STURIS, J. & BELL, G.I. (1996). Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. New Engl. J. Med., 334, 777-783.
11. SALTIEL, A.R. & OLEFSKY, J.M. (1996). Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45, 1661-1669.
12. SMITH, S.A., LISTER, C.A., HUGHES, M.G. & BUCKINGHAM, R.E. (1997). The PPARγ agonist, BRL 49653, prevents progression to diabetes in Zucker diabetic fatty rats. Diabetologia, 4 (suppl 1). A46.
13. SREENAN, S., STURGIS, J., PUGH, W., BURANT, C.F. & POLONSKY, K.S. (1996). Prevention of hyperglycemia in the Zucker diabetic fatly rat by treatment with metformin or troglitazone. Am. J. Physiol., 271, E742-E747.
14. TERRETTAZ, J. & JEANRENAUD, B. (1983). In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology, 112, 1346-1351.
15. UPTON, R., WIDDOWSON, P.S., KADOWAKI, S. & WILLIAMS, G. (1997). Improved insulin sensitivity in Zucker and ZDF rats following chronic treatment with the novel thiazolidinedione. MCC-555. Brit. J. Pharmacol., 122, 149P.
16. WHITCOMB, R.W. & SALTIEL, A.R. (1995). Ontologic, endocrine and metabolic: thiazolidinediones. Exp. Opin. Invest. Drugs, 4, 1299-1309.
17. WILLIAMS, G. (1994). Management of NIDDM. Lancet, 343, 95-100.
18. YKI-JÄRVINEN, H. & WILLIAMS, G. (1997). Insulin resistance in non-insulin-dependent diabetes mellitus. In Textbook of diabetes. eds. J. Pickup & G. Williams, pp. 20.1-20.13. Oxford: Blackwell Science Ltd.